Insys Therapeutics CEO and chairman John N. Kapoor to retire
Dr. Kapoor will remain a member of the Board and will Chair the newly formed Science and Research and Development Committee of the Board.
In connection with Dr. Kapoor’s retirement, the Board has appointed Santosh Vetticaden as Interim Chief Executive Officer and Steven Meyer as Chairman of the Board.
Dr. Vetticaden joined the Company in April 2015 and currently serves as the Company’s Chief Medical Officer.
He has pursued a passion for drug development and commercialization for over 20 years in diverse areas ranging from cardiovascular disease, infectious disease and orphan drug development for hemophilia and pediatric epilepsy.
Dr. Vetticaden has previously served as the Chief Medical Officer for multiple public companies and has held leadership positions at Johnson & Johnson, Aventis (now Sanofi), Cubist Pharmaceuticals and has previously served on the board of Amplyx Pharmaceuticals, a private biotech company.
Dr. Vetticaden currently serves on the board of Public Health Foundation Enterprise a non-profit organization devoted to population health.
He received his PhD from the Virginia Commonwealth University, his MD from the University of Maryland and his MBA from the Sloan School of Management at the Massachusetts Institute of Technology.
Mr. Meyer has served on the Board since November 2010 and currently serves as Chair of the Audit Committee as well as a member of the Compliance Committee.